Westchester Capital Management (New York)’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Westchester Capital Management (New York)’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,390,000	Closed	-$15.1M	–	353
2023 Q3	$15.1M	Hold	1,390,000	–	–	0.44%	41
2023 Q2	$14.8M	Buy	1,390,000 +83,406	+6%	+$877K	0.47%	43
2023 Q1	$13.6M	Buy	1,306,594 +1,142,351	+696%	+$11.8M	0.41%	46
2022 Q4	$1.69M	Buy	+164,243	New	+$1.67M	0.05%	307

Westchester Capital Management (New York)'s BIOS Position: Q4 2023 in Review

Westchester Capital Management (New York) sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 1,390,000 shares — an estimated $15.1M sold.

Westchester Capital Management (New York) first reported a position in BIOS in Q4 2022 and held it in 4 quarters. The position peaked at $15.1M in Q3 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Westchester Capital Management (New York) reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Westchester Capital Management (New York) sold 1,390,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $15.1M.
Westchester Capital Management (New York) first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q4 2022 and held it in 4 quarters.
Westchester Capital Management (New York)'s BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $15.1M in Q3 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2023, filed 15 Feb 2024.